Chronic thromboembolic pulmonary disease (CTEPD) [1] is a newly described disease entity belonging to a broader group of diseases affecting the pulmonary arterial vasculature as a result of PE [1,2]. CTEPD is defined as imaging evidence of persistent pulmonary arterial obstruction at any level despite at least 4 months of effective anticoagulation, combined with symptoms of cardiorespiratory impairment without resting pulmonary hypertension (PH) [3]. Chronic thromboembolic pulmonary hypertension (CTEPH) is a CTEPD associated with PH at rest, while the “post-PE-syndrome” (PPES) refers to all PE patients with persistently declined functional status in the absence of any thrombotic obstruction in the pulmonary vasculature [3].
